Pancreatic Cancer: Key Risk Factors and Emerging Treatment Advances

Pancreatic cancer arrives quietly. By the time most people know it's there, it has already spread. In Portugal, roughly 1,400 people receive this diagnosis each year, making it the third most common malignancy of the digestive system. The disease announces itself through symptoms so ordinary—abdominal pain, loss of appetite, weight loss, fatigue—that patients often mistake them for something else entirely. Many feel nothing at all in the early stages. This silence is the disease's greatest advantage. When doctors finally identify it, four out of five patients already have advanced cancer. Only one in five arrives at the clinic early enough to be a candidate for surgery, the only treatment that offers a real chance at cure.

Age is the primary accomplice. Most cases emerge after seventy, and men develop the disease more often than women. But age alone does not determine fate. Smoking stands as the single most modifiable risk factor—the one thing a person can actually control. Obesity follows close behind. Chronic alcohol consumption, particularly in those with a history of pancreatitis, diabetes, a diet heavy in animal fats, and a sedentary life all tilt the odds toward illness. About one in ten patients carry a family history of pancreatic cancer, though fewer than five percent inherit a specific genetic syndrome that predisposes them to it. The arithmetic is sobering: roughly two-thirds of the risk factors that drive this disease are theoretically preventable.

Diagnosis requires detective work. When suspicion arises, doctors typically order a CT scan or MRI to search for abnormalities. If something appears, endoscopic ultrasound allows them to examine the lesion more closely and extract tissue samples for analysis. For people at high genetic risk—those with a family history or known hereditary syndromes—screening programs exist, though they remain confined to research settings rather than routine clinical practice.

Treatment has no single answer. Surgery offers the only genuine path to cure, but most patients cannot have it. For them, chemotherapy becomes the mainstay, sometimes alone, sometimes paired with radiation. Here is where recent progress matters. New chemotherapy regimens administered before surgery have begun to shrink tumors and convert some previously inoperable cases into surgical candidates. The proportion of patients eligible for potentially curative surgery has grown. Clinical trials, increasingly available at Portuguese hospitals, offer another avenue for those willing to pursue experimental approaches.

The molecular revolution is underway. Over the past decade, researchers have identified biomarkers that predict how individual tumors will behave and how they might respond to specific drugs. These discoveries allow doctors to match treatments to the genetic fingerprint of each cancer rather than applying a one-size-fits-all approach. Survival rates, though still modest, have improved steadily. The disease that once seemed immutable is beginning to yield to precision medicine.

What comes next remains unwritten. The convergence of better chemotherapy, improved surgical techniques, and molecular understanding suggests that the natural history of pancreatic cancer—the way it develops, spreads, and kills—may transform within the next few years. Two-thirds of the risk factors are modifiable. That means prevention is possible. For those already diagnosed, the expanding toolkit of treatments and the accelerating pace of research offer something that did not exist a decade ago: genuine hope that the next generation of patients will fare better than the last.